PROTACs
PROTAC (PROteolysis-TArgeting Chimera) is a heterobifunctional nanomolecule containing two different ligands, ligand for ubiquitin E3 and ligand for target protein. The two parts are connected by linker to form a "three-unit" polymer, target protein ligand-linker-E3 ligase ligand. Building blocks of PROTAC molecules include PROTAC Linker, Ligand for Target Protein for PROTAC, Ligand for E3 Ligase, E3 Ligase Ligand-Linker Conjugate, Target Protein Ligand-Linker Conjugate, etc.
PROTACs Isoform Specific Products
All Product Categories
-
PROTACs 관련 제품 (1355)
관련 제품 (1355)
-
Antibodies (1)
-
PROTACs Isoform Comparison
-
PROTAC IRAK4 degrader-2
0 ImagesCat. No.: HY-135382CAS No.: 2374122-27-5PROTAC IRAK4 degrader-2 (Compound 9) is a PROTAC-based IRAK4 degrader that affords potent IRAK4 degradation with a DC50 in peripheral blood mononuclear cells (PBMCs) cells of 151 nM. PROTAC IRAK4 degrader-2 induce a reduction of IRAK4 protein levels with a DC50 of 36 nM in PBMC cells. PROTAC IRAK4 degrader-2 also leads to the inhibition of multiple cytokines in PBMCs.
-
BCL6 PROTAC 1
0 ImagesCat. No.: HY-122829CAS No.: 2257479-54-0
-
PROTAC EGFR degrader 6
0 ImagesCat. No.: HY-146423CAS No.: 2409793-28-6PROTAC EGFR degrader 6 is a PROTAC-based degrader and inducer targeting EGFRdel19. PROTAC EGFR degrader 6 induces the degradation of EGFRdel19 via the ubiquitin-proteasome system. PROTAC EGFR degrader 6 induces apoptosis. PROTAC EGFR degrader 6 arrests cells at the G1 phase. PROTAC EGFR degrader 6 can be used in research related to non-small cell lung cancer.
-
KTX-612
0 ImagesCat. No.: HY-148277CAS No.: 2573298-14-1
-
ZW-18-116
0 ImagesCat. No.: HY-180550ZW-18-116 (compound 9) is a dual-target PROTAC degrader for the oncoproteins TRKA and RET. ZW-18-116 induces the degradation of oncoproteins TRKA and RET by recruiting the CRBN E3 ligase. ZW-18-116 exhibits potent anti-proliferative activity in various cancer cell lines harboring RET or TRKA fusions. ZW-18-116 can be used for RET or TRKA-derived cancer research, such as thyroid, lung, and colon cancers.
-
PROTAC JAK2 degrader-1
0 ImagesCat. No.: HY-174428PROTAC JAK2 degrader-1 is a JAK2 PROTAC degrader, with a DC50 of 27.35 nM. PROTAC JAK2 degrader-1 induces JAK2 degradation via the ubiquitin-proteasome pathway. PROTAC JAK2 degrader-1 inhibits the JAK2-STAT signaling pathway. PROTAC JAK2 degrader-1 induces G2/M phase arrest and apoptosis in cancer cells. PROTAC JAK2 degrader-1 exhibits antiproliferative activity against cancer cells. PROTAC JAK2 degrader-1 inhibits recombinant human erythropoietin (rhEPO)-mediated polycythemia and splenomegaly in mice. PROTAC JAK2 degrader-1 can be used for research on myeloproliferative neoplasms, including polycythemia vera.
-
PROTAC BCL6 Degrader-4
0 ImagesCat. No.: HY-184007CAS No.: 3121287-19-9PROTAC BCL6 Degrader-4 is a potent PROTAC BCL6 degrader. PROTAC BCL6 Degrader-4 recruits CRBN E3 ligase machinery to promote ubiquitination and proteasomal degradation of BCL6. PROTAC BCL6 Degrader-4 can be used for the research of diffuse large B-cell lymphoma and related hematological malignancies.
-
AH081
0 ImagesCat. No.: HY-170859AAH081 (Compound 38) is a CK1δ/ε PROTAC degrader. AH081 is the negative control compound of AH078 (HY-170859). AH081 has inhibitory but no degradation activity for CK1δ/ε by using an inactive stereoisomer of the VHL ligand. Pink: CK1δ/ε ligand (HY-148251); Blue: VHL ligase ligand (HY-125845B); Black: linker
-
Vrucaparib-TP4
0 ImagesCat. No.: HY-130647CAS No.: 2410557-03-6
-
SJ46420
0 ImagesCat. No.: HY-168635SJ46420 is a BRD3 PROTAC degrader with a DC50 of 224 nM in U2OS cells. SJ46420 selectively mediates BRD3 degradation, exerts only partial effects on BRD2 and BRD4, and its activity is dependent on KLHDC2. SJ46420 is a prodrug variant of SJ46421 (HY-168634). SJ46420 can be used in the research of prostate cancer.
-
PROTAC 20S proteasome subunit β5 degrader 1
0 ImagesCat. No.: HY-169134PROTAC 20S proteasome subunit β5 degrader 1 is a PROTAC degrader targeting the 20S proteasome subunit β5, with a DC50 of 0.11 μM. PROTAC 20S proteasome subunit β5 degrader 1 forms a ternary complex with the CRBN E3 ligase, induces ubiquitination of the 20S proteasome subunit β5, and promotes its degradation via the proteasomal pathway. PROTAC 20S proteasome subunit β5 degrader 1 disrupts cell cycle progression, promotes apoptosis, and inhibits cell proliferation and migration. PROTAC 20S proteasome subunit β5 degrader 1 exhibits significant proliferation-inhibitory activity against various tumor cells, suppresses tumor growth in in vivo xenograft models, and overcomes the resistance of multiple myeloma cells to Bortezomib (HY-10227). PROTAC 20S proteasome subunit β5 degrader 1 can be used in studies related to pharyngeal cancer and drug-resistant multiple myeloma.
